Monday, September 30, 2013

Relypsa Files For IPO

Redwood City-based Relypsa has filed for an IPO, saying that it is looking to raise up to $126.5M in its initial public offering on the NASDAQ Global Market. The company, which is developing non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases, has not yet selected a trading symbol. The company's IPO is being underwritten by Morgan Stanley, BofA Merrill Lynch, Cowen and Company, Stifel, and Wedbush PacGrow Life Sciences. The company's backers include OrbiMed, 5AM Ventures, Delphi Ventures, New Leaf Ventures, Sprout Capital and Sibling Capital.